Slide 1: Microbot Medical conference cover
microbot INT CONFERENCE! 017. meen YORK PA CE “HOTEL
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS micropot ‘THIS DOCUMENT IS PRIVATE AND CONFIDENTIAL, CONTAINS SENSITIVE BUSINESS INFORMATION OF MICROBOT MEDICAL INC. [(MICROBOT) ANO IS NOT FOR PUBLIC DISTRIBUTION. This cocumanthas been prepared for informational purposes only and is provided personally'o you. By accepti
Slide 3: Microbot Medical
microbot medical
Slide 4: The Initial Spark...
THE INITIAL SPARK... microbot
Slide 5: Evolution of Surgery...
EVOLUTION OF SURGERY... microbot ...and the revolution of robotics in healthcare S Tomorrow Micro-robotics Today Robot Assisted Surgery 1990-2000 Minimally invasive Surgery 1980-1990 Freehand Surgery
Slide 6: Micro-Robotics Applications
MICRO-ROBOTICS APPLICATIONS ‘medical | ea | Drug Delivery Marking Sensing _Electrodes. Biomedical micro-robotics applications Hyperthermia ‘Stem Cells,
Slide 7: The Next Big-Small Thing
THE NEXT BIG-SMALL THING micropot @ Minimally Invasive Surgery (MIS) is one of the largest trends in surgical healthcare ‘® Global market for MIS devices in 2012 was valued at USD $25.03 Billion and is expected to reach a market value of USD $50.60 Billion by 2019. The MIS market is expected to grow
Slide 8: Solid Execution of Milestones
micr SOLID EXECUTION OF MILESTONES Since becoming a public company nine months ago, Microbot Medical has already executed on a number of objectives within the stated timeline: @ Inifiated the pre-clinical studies of first product, the Self-Cleaning Shunt ® Strengthened assets through expanded IP por
Slide 9: Microbot Medical
microbot medical
Slide 10: Investment Considerations
INVESTMENT CONSIDERATIONS microbot Developing two micro-invasive medical robotic technology platforms to enhance clinician ability to treat patients with unmet medical needs Potential pipeline designed to deliver additional solutions to other medical conditions every 12-24 months Proven leadership t
Slide 11: Technology Platforms
TECHNOLOGY PLATFORMS ViRob ® Autonomous Advancing Micro-Robot (AAMR) ® ViRob demonstrates the ability to advance within cavities similar to the typical human body's lumens TipCAT ® TipCAT is a disposable, flexible, self-propelled, see & treat endoscopelcatheter
Slide 12: A |e || om) |
i 3 2 i z 3 3 2 zg 3 A |e || om) | fo Loon ©
Slide 13: ViRob
ViRob Life in motion
Slide 14: VP Shunt Market Opportunity
VP SHUNT MARKET OPPORTUNITY ‘® Hydrocephalus and Normal Pressure Hydrocephalus (NPH), are medical conditions in which there is an abnormal accumulation of cerebrospinal fluid (CSF) in the ventricles of the brain. \@ Hydrocephalus occurs in about 1 in every 500 births in the U.S. alonet2 ®@ Over 1,00
Slide 15: Current Shunt Technology
CURRENT SHUNT TECHNOLOGY ® Ashunt is a tube, usually silicon, which moves, or allows movement of, fluid from one part of the body to another Ventricular Catheter Ventricte ‘Shunt Valve Catheter CSF flow i eritoneal cavity Distal Catheter ® Shunt products have changed little since the 1950's
Slide 16: Current Shunt Failure
CURRENT SHUNT FAILURE ViRob Approximately 50% of shunts in the pediatric population fail within two years of placement and repeated neurosurgical iN operations are often : required’ Ventricular catheter blockage is by far the most frequent event?
Slide 17: ViRob First Product
VIROB FIRST PRODUCT ViRob @ Self Cleaning Shunt (SCS) @ Anovel shunt technology for the continuous prevention of shunt blockage in hydrocephalus and NPH patients
Slide 18: Self Cleaning Shunt (SCS) - Lab Study
SELF CLEANING SHU ViRob (SCS) - LAB STUDY SCS showed the ability to prevent blockage on a shunt opening AVERAGE BLOCKAGE 100 90 80 70 60 Blockage percentage [%] scs2 scs3 scs4 cuit mscs4 = Control 4
Slide 19: Self Cleaning Shunt (SCS) - Lab Study
SELF CLEANING SHUNT (SCS) — LAB STUDY ViRob il Hydrocephalus 2014 wer Bristol Laboratory Testing of Micro-Robotic Self-Cleaning Shunt UK Shunt Testing Lab, Cambridge University, UK CONCLUSIONS: “Microbot Medical SCS presents low hydrodynamic resistance. The SCS behaves as a standard ventricular cath
Slide 20: TipCAT
Slide 21: North American colonoscope and upper GI endoscope segments
© The North American colonoscope ~ and upper GI endoscope segments are valued at about $600 million." n 15 and 20 million endoscopy proc res /are,conducted with reusable endo: devi to screen various components ¢ patient's Gl tract in the USA? 1 sem anescan Penme wet esc Rep. pie mize he res ee each
Slide 22: The Unmet Need
THE UNMET NEED Detection Rate: Cross-Contamination: The ‘GI Gap’ Approximately Named the #1 health Growing shortage 30% of polyps are technology hazard of gastroenterologists missed during Standard of 2016. The reported and increasing Colonoscopy (SC), patient volume e.g., due to polyps er affecting
Slide 23: Cross-Contamination in the News
CROSS-CONTAMINATION IN THE NEWS TipCAT Companies’ tests used in "superbug" soope cleaning flawed -FDA hospital cical scopes: Kk superbug CRE
Slide 24: First Application
FIRST APPLICATION Gastrointestinal Endoscopy Procedures Colonoscopy Examining the entire colon, from the rectum to the cecum, must include the proximal colon to the splenic flexure, and it may include the terminal ileum. ©
Slide 25: The Solution
THE SOLUTION The TipCAT colonoscope innovation is driven by two proprietary concepts ® ASemi-disposable design —With diagnostic and operative capabilities — Eliminate the need for cleaning / reprocessing @ Asimple self-propulsion mechanism — Easy operation + Allows a Physician Assistant (PA)/Nurse t
Slide 26: Self-Propelling Through 1.3M of a Pig's Colon
SELF-PROPELLING THROUGH 1.3M (~50 INCHES) OF A PIG’S COLON
Slide 27: Microbot
microbot
Slide 28: Robust IP Platform
ROBUST IP PLATFORM microb US PATENTIAPP NO. OTHER COUNTRIES usaost.t18 | Granted EP ex rR. as.m. CA JP, CN “Tp Propatad Devoe for Maton Though a Paesape isomme | Soeen tal Chane Desi Mon Though Pasape US882218| crate cem. table Salen Devo and Apso a Misti Imaging System use317.s88 ‘Ser Disposable En
Slide 29: Proven Leadership Team
PROVEN LEADERSHIP TEAM micros Prof. Moshe Shoham ‘Member of the Scientife Advisory Board ‘& Co-Founder Prof. Shoham isa worldwide acclaimed authori inthe feld of robotics, conducting ‘research in the robotic fala for over the past 20 years, with 2 special focus on kinematics and dynamics of robois.
Slide 30: Proven Leadership Team
PROVEN LEADERSHIP TEAM micros David Ben Naim CFO IM. Ben Naim is 8 CPA licensed in the ‘Sate of Israel. Prior to joining Microbot ‘Medical, Mr. Ben Naim operated DEN. Financia © Previously served as CFO of insuline Masia Ls, public company listed on the Tel-Aviv Stook Exchange CTASEINSL) |© Priocto
Slide 31: Near-Term Catalysts
NEAR-TERM CATALYSTS microbot @ Completing the Self Cleaning Shunt studies at Washington University (St. Louis) and Wayne State University (Detroit) — Presenting initial data at the International Society for Hydrocephalus and Cerebrospinal Fluid Disorders annual meeting, which is being held in Kobe,
Slide 32: Investment Considerations
INVESTMENT CONSIDERATIONS microbot Developing two micro-invasive medical robotic technology platforms to enhance clinician ability to treat patients with unmet medical needs Potential pipeline designed to deliver additional solutions to other medical conditions every 12-24 months Proven leadership t
Slide 33: Microbot
microbot